Prof. Namshik Han

Professor Namshik Han is a Korean-born computational scientist and entrepreneur, and the Co-Founder and CTO of CardiaTec Biosciences, a Cambridge-based TechBio company pioneering AI-driven drug discovery for cardiovascular disease. He leads the AI and Computational Biology group at the Milner Therapeutics Institute, University of Cambridge, and serves as Associate Faculty at the Cambridge Centre for AI in Medicine, and as an Adjunct Professor at Yonsei University College of Medicine in South Korea. His research integrates machine learning, network biology, and quantum algorithms to analyse large-scale multi-modal biomedical data and accelerate therapeutic discovery.

Professor Han co-founded CardiaTec in 2021 alongside CEO Raphael Peralta and COO Thelma Zablocki, building on over a decade of research into cardiovascular disease biology. CardiaTec leverages a proprietary human heart tissue multi-omics dataset — generated through a network of over 65 hospitals across the US and UK — to identify novel drug targets for cardiovascular conditions, the leading cause of death globally. The company's computational platform spans genomics, epigenomics, transcriptomics, and proteomics to model disease mechanisms at unprecedented depth.

In September 2024, CardiaTec closed a $6.5 million seed round led by Montage Ventures, with participation from Laidlaw Scholars Ventures, Apex Ventures, and Continuum Health Ventures. Professor Han is also co-founder of KURE.ai Therapeutics and a founding scientist of Storm Therapeutics, reflecting his commitment to translating cutting-edge academic AI research into real-world biomedical impact.